Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort

View ORCID ProfileTingyan Wang, View ORCID ProfileDavid A Smith, View ORCID ProfileCori Campbell, View ORCID ProfileJolynne Mokaya, Oliver Freeman, View ORCID ProfileHizni Salih, View ORCID ProfileAnna L McNaughton, Sarah Cripps, View ORCID ProfileKinga A Várnai, Theresa Noble, View ORCID ProfileKerrie Woods, Jane Collier, Katie Jeffery, View ORCID ProfileJim Davies, View ORCID ProfileEleanor Barnes, View ORCID ProfilePhilippa C Matthews
doi: https://doi.org/10.1101/2020.12.11.20247940
Tingyan Wang
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tingyan Wang
David A Smith
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David A Smith
Cori Campbell
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cori Campbell
Jolynne Mokaya
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jolynne Mokaya
Oliver Freeman
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
4Nuffield Department of Population Health, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hizni Salih
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
4Nuffield Department of Population Health, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hizni Salih
Anna L McNaughton
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna L McNaughton
Sarah Cripps
5Pharmacy Department, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kinga A Várnai
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kinga A Várnai
Theresa Noble
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerrie Woods
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kerrie Woods
Jane Collier
6Department of Hepatology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie Jeffery
7Department of Infectious Diseases and Microbiology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Davies
2NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford, Oxford, United Kingdom
8Department of Computer Science, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jim Davies
Eleanor Barnes
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eleanor Barnes
  • For correspondence: ellie.barnes@ndm.ox.ac.uk
Philippa C Matthews
1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
7Department of Infectious Diseases and Microbiology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippa C Matthews
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Aim Current clinical recommendations suggest treating chronic hepatitis B virus (HBV) infection in a minority of cases, but more data are needed to determine the benefits and risks of Tenofovir disoproxil fumarate (TDF) therapy. We aimed to assess the impact of TDF on liver disease, and the risk of nephrotoxicity.

Method We studied a longitudinal UK chronic HBV (CHB) cohort attending out-patient clinics between 2005 and 2018, analysing data for 206 ethnically diverse adults (60 on TDF, 146 untreated), with median follow-up 3.3±2.8 years.

Results Patients prescribed TDF were older (39 vs. 35 years, p=0.004) with a male excess (63% vs. 47%, p=0.04) compared to untreated patients. Reflecting treatment eligibility criteria, at baseline, treated patients were more likely to have elevated ALT (p<0.001), higher HBV DNA viral load (VL) (p<0.001), and higher elastography scores (p=0.002), but with no difference in renal function (p=0.6). In the TDF group, VL declined significantly between baseline and subsequent time points (all p<0.0001) with VL suppressed in 94% at three years, while in the untreated group viraemia was unchanged from baseline. In the TDF group, ALT and elastography scores normalised during treatment and by three years were equivalent to those in the untreated group. Progression of liver fibrosis did not occur in the TDF group but arose in 7.4% of untreated patients, although this difference was non-significant. There was no significant difference in renal impairment during follow-up between two groups.

Conclusion TDF may have long-term benefits for a wider pool of the CHB population.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work has been supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Oxford and funded by the NIHR Health Informatics Collaborative (HIC). C.C reports funding from GlaxoSmithKline. E.B is supported by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. P.C.M is supported by a Wellcome intermediate fellowship (grant ref 110110/Z/15/Z). The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors would like to thank all the research nurses and research admin staff at the contributing site for their help in data collection and Gail Roadknight for her work supporting the NIHR HIC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research database for the NIHR HIC viral hepatitis theme was approved by South Central - Oxford C Research Ethics Committee (REF Number: 15/SC/0523).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest Statement: None

Data Availability

No additional data are available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 14, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort
Tingyan Wang, David A Smith, Cori Campbell, Jolynne Mokaya, Oliver Freeman, Hizni Salih, Anna L McNaughton, Sarah Cripps, Kinga A Várnai, Theresa Noble, Kerrie Woods, Jane Collier, Katie Jeffery, Jim Davies, Eleanor Barnes, Philippa C Matthews
medRxiv 2020.12.11.20247940; doi: https://doi.org/10.1101/2020.12.11.20247940
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort
Tingyan Wang, David A Smith, Cori Campbell, Jolynne Mokaya, Oliver Freeman, Hizni Salih, Anna L McNaughton, Sarah Cripps, Kinga A Várnai, Theresa Noble, Kerrie Woods, Jane Collier, Katie Jeffery, Jim Davies, Eleanor Barnes, Philippa C Matthews
medRxiv 2020.12.11.20247940; doi: https://doi.org/10.1101/2020.12.11.20247940

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)